Post-hoc analyses of shifts in ACR responses and DAS28 (ESR) states between year 1 and year 2, following switch from infliximab to abatacept
| ACR response* at year 1 | Shifts in ACR response* by year 2, n (%) | ||||
|---|---|---|---|---|---|
| Total, n (%) | No response | ACR20 (not ACR50/70) | ACR50 (not ACR70) | ACR70 | |
| No response | 39 (30.7) | 10 (25.6) | 11 (28.2) | 13 (33.3) | 5 (12.8) |
| ACR 20 (but not ACR50/70) | 32 (25.2) | 7 (21.9) | 5 (15.6) | 9 (28.1) | 11 (34.4) |
| ACR 50 (but not ACR70) | 24 (18.9) | 3 (12.5) | 1 (4.2) | 8 (33.3) | 12 (50.0) |
| ACR 70 | 32 (25.2) | 0 | 0 | 3 (9.4) | 29 (90.6) |
| DAS28 (ESR) status* at year 1 | Shifts in DAS28 (ESR) status* by year 2, n (%) | ||||
| Total, n (%) | HDAS (DAS28 >5.1) | MDAS (DAS28 >3.2–5.1) | LDAS (DAS28 2.6–3.2) | Remission (DAS28 <2.6) | |
| HDAS (DAS28 >5.1) | 39 (31.2) | 8 (20.5) | 25 (64.1) | 2 (5.1) | 4 (10.3) |
| MDAS (DAS28 >3.2–5.1) | 56 (44.8) | 4 (7.1) | 25 (44.6) | 15 (26.8) | 12 (21.4) |
| LDAS (DAS28 2.6–3.2) | 12 (9.6) | 1 (8.3) | 4 (33.3) | 1 (8.3) | 6 (50.0) |
| Remission (DAS28 <2.6) | 18 (14.4) | 0 | 1 (5.6) | 3 (16.7) | 14 (77.8) |
↵* ACR response and DAS28 status categories are discrete.
ACR, American College of Rheumatology; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HDAS, high disease activity state; LDAS, low disease activity state; MDAS, moderate disease activity state.